A blood cooling device

Abstract

The blood cooling device provided by the application comprises a first cooling unit, a second cooling unit, a third cooling unit and a fourth cooling unit, any one of the cooling units comprises a constant-temperature cavity, a blood pipeline arranged in the constant-temperature cavity and a composite phase change material distributed in the constant-temperature cavity, the blood cooling device provided by the application utilizes four kinds of composite phase change cold storage materials with gradient distribution of melting points, so that the blood passing through the blood cooling device is cooled in four stages, the temperature difference between the blood and the cold surface in the whole cooling process does not exceed 15 DEG C, the blood temperature before and after each stage of cooling can be fixed in a preset range, and finally the output temperature is about 4 DEG C. Since the phase change material has natural energy storage and cold storage capacity, the cold quantity can be released when needed, so that the ability of the device to cope with different working conditions and abnormal cold / heat shocks caused by factors such as faults is enhanced.

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of medical devices, in particular to a blood cooling device. BACKGROUND

[0002] Brain ischemia caused by stroke (commonly known as stroke) is a major killer of human life and health safety worldwide, among which stroke refers to a series of brain diseases caused by brain blood circulation disorder due to rupture or blockage of cerebral blood vessels. Stroke often occurs in the elderly population, and with the continuous improvement of population aging, its incidence and mortality are greatly increased. In addition to high incidence and high mortality, the disability rate of stroke is also high. Even if there is no death, the patients are likely to suffer from various serious sequelae, including paralysis, language disorders and behavior disorders, which greatly reduces the quality of life of patients.

[0003] The medical community has proven that hypothermia can reduce cell oxygen consumption and inhibit harmful cell biochemical mechanisms, and has a clear neuroprotective effect on patients with brain ischemia or brain injury. Timely brain cooling can save patients' lives and significantly improve patients' prognosis.

[0004] At present, 4-10℃ hypothermia is the preferred temperature for perfusion in many vascular surgery operations. In addition to specially designed perfusion fluid, direct supply of cooled patient's own blood to the brain blood vessels through a catheter is an effective cooling method. SUMMARY

[0005] In view of this, it is necessary to provide a blood cooling device that can work efficiently and stably in view of the defects in the prior art.

[0006] To solve the above problems, the technical scheme adopted by the present application is as follows:

[0007] The present application provides a blood cooling device, comprising a first cooling unit, a second cooling unit, a third cooling unit and a fourth cooling unit, wherein:

[0008] The first cooling unit comprises a first constant temperature cavity, a first blood pipeline arranged in the first constant temperature cavity and a first composite phase change material distributed in the first constant temperature cavity, and the melting point of the first composite phase change material is 25℃;

[0009] The second cooling unit comprises a second constant temperature cavity, a second blood pipeline arranged in the second constant temperature cavity and a second composite phase change material distributed in the second constant temperature cavity, and the melting point of the second composite phase change material is 15℃;

[0010] The third cooling unit comprises a third constant temperature cavity, a third blood conduit arranged in the third constant temperature cavity, and a third composite phase change material distributed in the third constant temperature cavity, the melting point of the third composite phase change material being 8℃;

[0011] The fourth cooling unit comprises a fourth constant temperature cavity, a fourth blood conduit arranged in the fourth constant temperature cavity, and a fourth composite phase change material distributed in the fourth constant temperature cavity, the melting point of the fourth composite phase change material being 4℃;

[0012] Blood enters from the inlet of the first blood conduit, and is connected between adjacent constant temperature cavities through the outlet of the blood conduit and the inlet of the next blood conduit;

[0013] Blood is cooled from the body temperature in sequence through the first cooling unit, the second cooling unit, the third cooling unit, and the fourth cooling unit.

[0014] In some embodiments, the material of the first constant temperature cavity, the second constant temperature cavity, the third constant temperature cavity, and the fourth constant temperature cavity comprises, but is not limited to, stainless steel and copper.

[0015] In some embodiments, fins are arranged on the inner wall of the first constant temperature cavity, the second constant temperature cavity, the third constant temperature cavity, and the fourth constant temperature cavity.

[0016] In some embodiments, the material of the first blood conduit, the second blood conduit, the third blood conduit, and the fourth blood conduit comprises, but is not limited to, stainless steel, and the shape comprises, but is not limited to, a straight pipe, an elbow pipe, or a spiral pipe.

[0017] In some embodiments, the first composite phase change material comprises the following components in mass percentage: 30-47.5% of EGaZn alloy, 47.5-65% of phase change paraffin, not more than 5% of expanded graphite, and nucleating agent, the melting point of the phase change paraffin being 25℃.

[0018] In some embodiments, the second composite phase change material comprises the following components in mass percentage: 30-47.5% of EGaIn alloy, 47.5-65% of phase change paraffin, not more than 5% of expanded graphite, and nucleating agent, the melting point of the phase change paraffin being 15℃.

[0019] In some embodiments, the third composite phase change material comprises the following components in mass percentage: 30-47.5% of Ga 61 In 25 Sn 13 Zn1 alloy, 47.5-65% of phase change paraffin, not more than 5% of expanded graphite, and nucleating agent, the melting point of the phase change paraffin being 25℃.

[0020] In some embodiments, the fourth composite phase change material comprises ingredients in the following mass percentages: 30-47.5% of Ga 71 In 15 Sn 13 Zn1 alloy, 47.5-65% of PEG-400, not more than 5% of expanded graphite, and a nucleating agent, the PEG-400 having a melting point of 25℃.

[0021] In some embodiments, the nucleating agent comprises but is not limited to metal powder or ceramic powder, the expanded graphite comprises clinker or clinker made from raw material by means including but not limited to microwave heating or muffle, the clinker is expanded graphite, and the raw material is expandable graphite.

[0022] In some embodiments, the first composite phase change material, the second composite phase change material, the third composite phase change material, and the fourth composite phase change material are in close contact with the corresponding blood pipeline.

[0023] In some embodiments, a thermal interface material is arranged between the first composite phase change material, the second composite phase change material, the third composite phase change material, and the fourth composite phase change material and the corresponding blood pipeline.

[0024] In some embodiments, the thermostatic cavities are isolated by a thermal insulation layer, which comprises but is not limited to vacuum insulation, thermal insulation cotton, or hollow glass plate.

[0025] In some embodiments, a refrigerator is further arranged on any of the thermostatic cavities, which comprises but is not limited to semiconductor refrigeration, cooling water refrigeration, or refrigeration cycle refrigeration.

[0026] In some embodiments, a temperature measuring device is further arranged in any of the thermostatic cavities, which comprises but is not limited to thermocouple or thermistor.

[0027] In some embodiments, the refrigerator further comprises a temperature control unit, which receives a temperature signal returned by the temperature measuring device, and determines whether to provide cold energy to maintain a low-temperature environment in the thermostatic cavity according to the temperature signal.

[0028] The application adopts the above technical solutions, and has the following beneficial effects:

[0029] The blood cooling device provided by the application comprises a first cooling unit, a second cooling unit, a third cooling unit and a fourth cooling unit, any one of the cooling units comprises a constant-temperature cavity, a blood pipeline arranged in the constant-temperature cavity and a composite phase change material distributed in the constant-temperature cavity, the blood cooling device provided by the application utilizes four composite phase change cold storage materials with gradient distribution of melting points, so that the blood passing through the four cooling stages, the temperature difference between the blood and the cold surface in the whole cooling process does not exceed 15 DEG C, the blood temperature before and after each cooling stage can be fixed in a preset range, and finally the output temperature of the blood is about 4 DEG C. Since the phase change material has natural energy storage and cold storage capacity, the cold quantity can be released when needed, thereby enhancing the ability of the device to cope with different working conditions and abnormal cold / heat shocks caused by factors such as failure. BRIEF DESCRIPTION OF DRAWINGS

[0030] In order to more clearly illustrate the technical solutions of the embodiments of the application, the following will briefly introduce the drawings needed to be used in the description of the embodiments of the application or the prior art. Obviously, the drawings described below are only some embodiments of the application, and for those skilled in the art, other drawings can also be obtained without creative labor on the basis of these drawings.

[0031] Figure 1 The principle schematic diagram of the blood cooling device provided by the embodiments of the application.

[0032] Figure 2 The structural schematic diagram of the blood cooling device provided by the embodiments of the application. DETAILED DESCRIPTION

[0033] The embodiments of the application will be described in detail below, and examples of the embodiments are shown in the drawings, wherein the same or similar reference signs represent the same or similar elements or elements with the same or similar functions throughout. The embodiments described below by referring to the drawings are exemplary and are intended to explain the application, and cannot be understood as a limitation of the application.

[0034] In the description of the application, it should be understood that the terms "upper", "lower", "horizontal", "inner", "outer" and the like indicate the orientation or positional relationship shown in the drawings, and are only for the purpose of facilitating the description of the application and simplifying the description, and do not indicate or imply that the device or element referred to must have a particular orientation, be constructed and operated in a particular orientation, therefore cannot be understood as a limitation of the application.

[0035] In addition, the terms "first", "second", etc. are used only for descriptive purposes and are not to be construed as indicating or implying relative importance or an indicated number of technical features. Thus, features defined with "first", "second" can include one or more of the features explicitly or implicitly. In the description of the present application, the meaning of "a plurality" is two or more, unless otherwise expressly and specifically limited.

[0036] In order to make the purpose, technical solutions and advantages of the present application more clear, the present application is further described in detail below in combination with the drawings and examples.

[0037] Please refer to Figure 1 and Figure 2 A schematic diagram of the principle and structure of a blood cooling device provided in the present embodiment includes a first cooling unit 10, a second cooling unit 20, a third cooling unit 30 and a fourth cooling unit 40. The specific structure of each unit is described in detail below.

[0038] The first cooling unit 10 includes a first constant temperature cavity 11, a first blood pipeline 12 arranged in the first constant temperature cavity 11 and a first composite phase change material 13 distributed in the first constant temperature cavity 11, and the melting point of the first composite phase change material is 25℃.

[0039] In some embodiments, the first composite phase change material 13 includes the following components with the mass percentage: 30-47.5% of EGaZn alloy, 47.5-65% of phase change paraffin, not more than 5% of expanded graphite and nucleating agent, and the melting point of the phase change paraffin is 25℃.

[0040] The second cooling unit 20 includes a second constant temperature cavity 21, a second blood pipeline 22 arranged in the second constant temperature cavity 21 and a second composite phase change material 23 distributed in the second constant temperature cavity 21, and the melting point of the second composite phase change material 23 is 15℃.

[0041] In some embodiments, the second composite phase change material 23 includes the following components with the mass percentage: 30-47.5% of EGaIn alloy, 47.5-65% of phase change paraffin, not more than 5% of expanded graphite and nucleating agent, and the melting point of the phase change paraffin is 15℃.

[0042] The third cooling unit 30 includes a third constant temperature cavity 31, a third blood pipeline 32 arranged in the third constant temperature cavity 31 and a third composite phase change material 33 distributed in the third constant temperature cavity 31, and the melting point of the third composite phase change material 33 is 8℃.

[0043] In some embodiments, the third composite phase change material 33 includes the following components with the mass percentage: 30-47.5% of Ga61 In 25 Sn 13 Zn1 alloy, 47.5-65% phase change paraffin wax, not more than 5% expanded graphite and nucleating agent, the melting point of the phase change paraffin wax is 25°C.

[0044] The fourth cooling unit 40 comprises a fourth constant temperature cavity 41, a fourth blood pipeline 42 arranged in the fourth constant temperature cavity 41 and a fourth composite phase change material 43 distributed in the fourth constant temperature cavity 41, and the melting point of the fourth composite phase change material 43 is 4°C.

[0045] In some embodiments, the fourth composite phase change material 43 comprises the following mass percentage of components: 30-47.5% Ga 71 In 15 Sn 13 Zn1 alloy, 47.5-65% PEG-400, not more than 5% expanded graphite and nucleating agent, the melting point of the PEG-400 is 25°C.

[0046] It can be understood that the composite phase change material provided by the above embodiments of the present application mainly comprises low melting point metal phase change materials and expanded graphite in addition to common organic cold accumulators and nucleating agents. The low melting point metal phase change materials have the advantages of high volume phase change latent heat and high thermal conductivity, and the presence of the low melting point metal phase change materials can improve the heat transfer capacity of the material; the expanded graphite has a mesoporous structure, can encapsulate phase change materials and form a high thermal conductivity skeleton, and significantly improves the stability and thermal conductivity of the material and improves the overall performance.

[0047] In some embodiments, the nucleating agent comprises but is not limited to metal powder or ceramic powder, the expanded graphite comprises clinker or clinker made from raw material by means including but not limited to microwave heating or muffle furnace, the clinker is expanded graphite, and the raw material is expandable graphite.

[0048] In some embodiments, the materials of the first constant temperature cavity 11, the second constant temperature cavity 21, the third constant temperature cavity 31 and the fourth constant temperature cavity 41 comprise but are not limited to stainless steel and copper.

[0049] It can be understood that the constant temperature cavity provided by the present embodiment has high thermal conductivity and is biologically safe.

[0050] In some embodiments, the inner walls of the first constant temperature cavity 11, the second constant temperature cavity 21, the third constant temperature cavity 31 and the fourth constant temperature cavity 41 are provided with fins to further optimize the heat transfer performance.

[0051] In some embodiments, the first blood conduit 12, the second blood conduit 22, the third blood conduit 32, and the fourth blood conduit 42 are made of stainless steel to ensure high thermal conductivity and biological safety.

[0052] Further, the first blood conduit 12, the second blood conduit 22, the third blood conduit 32, and the fourth blood conduit 42 are sized to meet the heat exchange requirement under maximum working condition, and the shape includes but is not limited to straight pipe, elbow pipe, or spiral pipe.

[0053] The blood cooling device provided by the above embodiments has the following working mode:

[0054] Blood (with an ex vivo temperature of 37°C) enters the first blood conduit 12 through the inlet, and is connected between adjacent constant temperature cavities through the outlet of the blood conduit and the inlet of the next blood conduit; the blood is cooled in sequence from the ex vivo temperature through the first cooling unit 10, the second cooling unit 20, the third cooling unit 30, and the fourth cooling unit 40.

[0055] In some embodiments, the first composite phase change material 13, the second composite phase change material 23, the third composite phase change material 33, and the fourth composite phase change material 43 are in close contact with the corresponding blood conduit to ensure better heat exchange performance.

[0056] In some embodiments, a thermal interface material is arranged between the first composite phase change material 13, the second composite phase change material 23, the third composite phase change material 33, and the fourth composite phase change material 43 and the corresponding blood conduit.

[0057] In some embodiments, the constant temperature cavities are isolated by an insulating layer 50, which includes but is not limited to vacuum insulation, thermal insulation cotton, or hollow glass plate.

[0058] In some embodiments, a refrigerator 60 is further arranged in any of the constant temperature cavities, and the refrigerator 60 includes but is not limited to semiconductor refrigeration, cooling water refrigeration, or refrigeration cycle refrigeration.

[0059] In some embodiments, a temperature measuring device 70 is further arranged in any of the constant temperature cavities, and the temperature measuring device 70 includes but is not limited to thermocouple or thermistor.

[0060] In some embodiments, the refrigerator 60 further includes a temperature control unit (not shown in the figure), which receives a temperature signal returned by the temperature measuring device 70, and determines whether to provide cooling capacity to maintain a low-temperature environment in the constant temperature cavity according to the temperature signal.

[0061] The blood cooling device provided by the application utilizes four kinds of composite phase change cold storage materials with gradient distribution of melting points to make the blood channel passing therethrough be cooled in four stages, so that the temperature difference between the blood and the cold surface in the whole cooling process does not exceed 15℃. The blood temperature before and after each stage of cooling can be fixed in a preset range, and the final output temperature is about 4℃. Since the phase change material has natural energy storage and cold storage capacity, the cold quantity can be released when needed, thereby enhancing the ability of the device to cope with different working conditions and abnormal cold / heat shocks caused by factors such as failure.

[0062] Embodiment 1

[0063] Please refer to Figure 2 A schematic diagram of one structure form of the blood cooling device provided by Embodiment 1 of the application, designed with a blood flow of 300mL / min.

[0064] The blood inlet temperature of the first constant temperature cavity 11 is 37℃, and the composite phase change material 13 filled in the first constant temperature cavity 11 contains 47.5% of EGaZn alloy, 47.5% of phase change paraffin, 2% of nucleating agent and 3% of expanded graphite in terms of mass percentage. The blood outlet temperature of the first constant temperature cavity 11 is designed to be 26℃. The first blood pipeline 12 is a stainless steel pipe with an inner diameter of 5mm. According to the above data, it can be calculated that the blood pipeline length required in the first constant temperature cavity 11 is 5m. In order to save space, the first blood pipeline 12 is fixed in the first composite phase change material 13 in the constant temperature cavity in the form of 16 turns with a diameter of 10cm and a pitch of 1cm, and thus the size of the first constant temperature cavity 11 is designed to be a cylindrical cavity with a diameter of 15cm and a height of 30cm. The cold storage capacity of the first composite phase change material 13 with the above volume can ensure that the device can provide cooling blood at the target temperature for ten minutes even if the refrigerator 60 stops working.

[0065] The blood inlet temperature of the second constant temperature cavity 21 is 26℃, and the composite phase change material 23 filled in the second constant temperature cavity 21 contains 47.5% of EGaIn alloy, 47.5% of phase change paraffin, 2% of nucleating agent and 3% of expanded graphite in terms of mass percentage. The blood outlet temperature of the second constant temperature cavity 21 is designed to be 15.5℃. The second blood pipeline 22 is a stainless steel pipe with an inner diameter of 5mm. According to the above data, it can be calculated that the blood pipeline length required in the second constant temperature cavity 21 is 5m. In order to save space, the second blood pipeline 22 is fixed in the second composite phase change material 23 in the constant temperature cavity in the form of 16 turns with a diameter of 10cm and a pitch of 1cm, and thus the size of the second constant temperature cavity 21 is designed to be a cylindrical cavity with a diameter of 15cm and a height of 30cm. The cold storage capacity of the second composite phase change material 23 with the above volume can ensure that the device can provide cooling blood at the target temperature for ten minutes even if the refrigerator 60 stops working.

[0066] Wherein: the blood inlet temperature of the third constant temperature cavity 31 is 15.5℃, the third composite phase change material 33 filled in the third constant temperature cavity 31 contains Ga 61 In 25 Sn 13 Zn1 alloy contains 47.5%, phase change paraffin contains 47.5%, nucleating agent contains 2%, and expanded graphite contains 3%. The blood outlet temperature of the third constant temperature cavity 31 is designed to be 8.4℃. The third blood pipeline 32 is a stainless steel pipe with an inner diameter of 5mm. According to the above data, it can be calculated that the length of the blood pipeline required in the third constant temperature cavity 31 is 5m. In order to save space, the third blood pipeline 32 is fixed in the third composite phase change material 33 in the constant temperature cavity in the form of a diameter of 10cm, a pitch of 1cm, and a total of 16 turns. Therefore, the size of the third constant temperature cavity 31 is designed to be a cylindrical cavity with a diameter of 15cm and a height of 30cm. The cold storage capacity of the third composite phase change material 33 with the above volume can ensure that the device can provide cooling blood at the target temperature for ten minutes even if the refrigerator 60 stops working.

[0067] Wherein: the blood inlet temperature of the fourth constant temperature cavity 41 is 37℃, the fourth composite phase change material 43 filled in the fourth constant temperature cavity 41 contains Ga 71 In 15 Sn 13 Zn1 alloy contains 47.5%, PEG-400 contains 47.5%, nucleating agent contains 2%, and expanded graphite contains 3%. The blood outlet temperature of the fourth constant temperature cavity 41 is designed to be 4.2℃. The fourth blood pipeline 42 is a stainless steel pipe with an inner diameter of 5mm. According to the above data, it can be calculated that the length of the blood pipeline required in the fourth constant temperature cavity 41 is 5m. In order to save space, the blood pipeline is fixed in the composite phase change material 43 in the fourth constant temperature cavity 41 in the form of a diameter of 10cm, a pitch of 1cm, and a total of 16 turns. Therefore, the size of the fourth constant temperature cavity 41 is designed to be a cylindrical cavity with a diameter of 15cm and a height of 30cm. The cold storage capacity of the composite phase change material with the above volume can ensure that the device can provide cooling blood at the target temperature for ten minutes even if the refrigerator stops working.

[0068] Wherein the temperature measuring device is Pt100, the refrigerator uses a 300W semiconductor refrigeration sheet, and the heat insulation layer material is glass fiber insulation cotton.

[0069] The above device inputs blood at a temperature of 37℃ and outputs blood at a temperature of 4.2℃, which is within an acceptable range of 5% difference from the target temperature of 4℃, and the temperature difference between the blood and the cold surface throughout the process does not exceed 15℃.

[0070] It can be understood that any combination of the technical features in the above-described embodiments can be made, and for the sake of brevity, not all possible combinations of the technical features in the above-described embodiments are described, however, as long as the combination of the technical features does not exist contradictory, it should be considered within the scope of the present disclosure.

[0071] The above are only the preferred embodiments of the present application, and only the technical principles of the present application are specifically described, and these descriptions are only for the purpose of explaining the principles of the present application, and cannot be interpreted in any way as a limitation on the scope of protection of the present application. Based on the explanation here, any modification, equivalent replacement and improvement made within the spirit and principle of the present application, and other specific embodiments of the present application which can be easily thought by those skilled in the art without creative labor, should be included in the protection scope of the present application.

Claims

1. A blood cooling device, characterized in that, The first cooling unit, the second cooling unit, the third cooling unit and the fourth cooling unit are arranged in sequence. The first cooling unit comprises a first constant temperature cavity, a first blood conduit arranged in the first constant temperature cavity and a first composite phase change material distributed in the first constant temperature cavity, and the melting point of the first composite phase change material is 25℃. The second cooling unit comprises a second constant temperature cavity, a second blood conduit arranged in the second constant temperature cavity and a second composite phase change material distributed in the second constant temperature cavity, and the melting point of the second composite phase change material is 15℃. The third cooling unit comprises a third constant temperature cavity, a third blood conduit arranged in the third constant temperature cavity and a third composite phase change material distributed in the third constant temperature cavity, and the melting point of the third composite phase change material is 8℃. The fourth cooling unit comprises a fourth constant temperature cavity, a fourth blood conduit arranged in the fourth constant temperature cavity and a fourth composite phase change material distributed in the fourth constant temperature cavity, and the melting point of the fourth composite phase change material is 4℃. Blood enters the first blood conduit from the inlet, and the adjacent constant temperature cavities are connected through the outlet of the blood conduit and the inlet of the next blood conduit. Blood is cooled from the ex vivo temperature through the first cooling unit, the second cooling unit, the third cooling unit and the fourth cooling unit in sequence. The first composite phase change material comprises the following components in mass percentage: 30-47.5% of EGaZn alloy, 47.5-65% of phase change paraffin, not more than 5% of expanded graphite and nucleating agent, and the melting point of the phase change paraffin is 25℃. The second composite phase change material comprises the following components in mass percentage: 30-47.5% of EGaIn alloy, 47.5-65% of phase change paraffin, not more than 5% of expanded graphite and nucleating agent, and the melting point of the phase change paraffin is 15℃. The third composite phase change material comprises the following components in mass percentage: 30-47.5% of Ga61In25Sn13Zn1 alloy, 47.5-65% of phase change paraffin, not more than 5% of expanded graphite and nucleating agent, and the melting point of the phase change paraffin is 25℃. The fourth composite phase change material comprises the following components in mass percentage: 30-47.5% of Ga71In15Sn13Zn1 alloy, 47.5-65% of PEG-400, not more than 5% of expanded graphite and nucleating agent, and the melting point of the PEG-400 is 25℃.

2. The blood cooling device of claim 1, wherein The materials of the first constant temperature cavity, the second constant temperature cavity, the third constant temperature cavity and the fourth constant temperature cavity include but are not limited to stainless steel and copper.

3. The blood cooling device of claim 2, wherein The inner walls of the first constant temperature cavity, the second constant temperature cavity, the third constant temperature cavity and the fourth constant temperature cavity are provided with fins.

4. The blood cooling device of claim 1, wherein, The materials of the first blood conduit, the second blood conduit, the third blood conduit and the fourth blood conduit include but are not limited to stainless steel, and the shapes include but are not limited to straight pipes, bent pipes or spiral pipes.

5. The blood cooling device of claim 1, wherein, The nucleating agent includes but is not limited to metal powder or ceramic powder, the expanded graphite includes clinker or clinker made by raw material through means including but not limited to microwave heating or muffle furnace, the clinker is expanded graphite, and the raw material is expandable graphite.

6. The blood cooling device of claim 1, wherein, The first, second, third and fourth composite phase change materials are in close contact with the corresponding blood conduits.

7. The blood cooling device of claim 6, wherein A thermal interface material is arranged between the first, second, third and fourth composite phase change materials and the corresponding blood conduits.

8. The blood cooling device of claim 1, wherein, The constant temperature cavities are isolated by an adiabatic layer including but not limited to vacuum adiabatic, thermal insulation cotton or hollow glass plate.

9. The blood cooling device of claim 1, wherein, A refrigeration device is further arranged on any of the constant temperature cavities, and the refrigeration device includes but is not limited to semiconductor refrigeration, cooling water refrigeration or refrigeration cycle refrigeration.

10. The blood cooling device of claim 9, wherein, A temperature measuring device is further arranged in any of the constant temperature cavities, and the temperature measuring device includes but is not limited to thermocouple or thermistor.

11. The blood cooling device of claim 10, wherein, The refrigeration device further includes a temperature control unit, which receives a temperature signal returned by the temperature measuring device and determines whether to provide cold energy to maintain a low-temperature environment in the constant temperature cavity according to the temperature signal.

Images